Buying pressure lifts Pfizer higher in today trading

Traders Union
All News
Financial News
Pfizer rises 2.00% today to $27.59

Highlights

The FDA granted Priority Review to Pfizer's HYMPAVZI (marstacimab), advancing its supplemental Biologics License Application for expanded use in hemophilia A treatment.
Pfizer reported Q4 earnings up 5% year-over-year despite a 3% operational revenue decline driven by sharply lower COVID-19 product sales.
Pfizer shares at $27.59 trade above key MAs, with bullish momentum and short-term resistance at $28.00; near-term downside supported at $26.10.

Earnings resilience and priority review bolster investor sentiment

The U.S. Food and Drug Administration accepted and granted Priority Review for Pfizer's supplemental Biologics License Application for HYMPAVZI (marstacimab), aimed at expanding its approval to treat hemophilia A. Pfizer also reported fourth-quarter results with a 5% year-over-year increase in earnings despite a 3% operational decrease in revenue due to sharply lower COVID-19 product sales. The company continues its record of 56 consecutive years of dividend payments, with 15 straight annual increases.

Anton Kharitonov, expert at Traders Union, sees technical strength in Pfizer trading well above all major moving averages but warns of stretched conditions. He notes the positive FDA news and steady dividends, yet is critical of underlying weaknesses, such as operational revenue decline and heavy dependence on nonrecurring COVID-19 income. The expert highlights overbought signals on Stochastic RSI and CCI, which point to a crowded long trade. Kharitonov is cautious about sustainability, given short-term volatility and the potential for a retracement below $26.10. "Despite upbeat headlines, I remain wary of upside exhaustion and advise a prudent, risk-managed approach at these levels."

Viktoras Karapetjanc, expert at Traders Union, believes Pfizer’s fundamental story is strong as the company expands its hemophilia portfolio with FDA Priority Review and demonstrates resilient earnings despite a challenging post-COVID environment. He sees confidence in the market’s response, underlined by a decades-long streak of dividend increases and supportive institutional flows. Karapetjanc notes that the bullish structure remains intact, with robust technicals confirming upward momentum and further growth potential. "With fundamentals and sentiment aligning, I expect the market to keep rewarding patient investors in the current uptrend."

Parshwa Turakhiya, analyst, observes active buying interest as Pfizer stays above all primary moving averages and approaches session highs. He spots opportunity in the near-term, citing a constructive setup with bullish momentum indicators, but also flags the risk of short-term pullback with overbought signals flashing. Turakhiya focuses on key where price may either consolidate or quickly test $28.00, keeping both breakout and retracement scenarios in view. "I see sentiment favoring trend followers, but nimble positioning is crucial as volatility could spike on any decisive move from current levels."

Overbought signals as momentum indicators reinforce upward bias

Momentum indicators for PFE are positive, with MACD and ADX pointing to ongoing bullish pressure and the daily RSI reading at 60, which confirms the upward bias. Overbought readings from the Stochastic RSI, CCI, and BBP highlight stretched short-term conditions, and the Awesome Oscillator supports the prevailing upward trend. Price action shows a gap up at the open, with the asset trading close to the session high of $27.63, reflecting moderate volatility and consistent demand throughout the day. Key support is at the Ichimoku Kijun near $26.10, with resistance seen toward the MA-50 and the round figure at $28.00.

Last time, analysts noted that Pfizer remains in a bullish trend, trading solidly above its key short-, medium-, and long-term moving averages with strong momentum confirmed by the MACD and ADX. However, while buyers retain control above primary support, overbought signals from oscillators suggest increased risk of a short-term pause or pullback near resistance.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.